Streetwise Expert Interviews

Ran Nussbaum

Buy Biotech When There's Blood on the Street: Pontifax's Ran Nussbaum

Ran Nussbaum, managing partner with The Pontifax Group, doesn't worry too much about overall market volatility. Biotechs, he feels, are somewhat immune to turmoil because their fundamentals are based in real life. He prefers to play on good science and unmet medical needs, and then sit tight until a stock is discovered. In this interview with The Life Sciences Report, Nussbaum describes a few takeover candidates primed for stellar growth, as well as promising names that are part of the movement toward personalized medicine.

(9/2/15) More >
Read More Streetwise Interviews

Novel Technology Platforms with Dramatic Growth Potential: Wedbush's David Nierengarten

Many novel ideas are now in the clinic, and have opened up fresh opportunities for dramatic industry growth, especially in the gene and cellular therapy realm. David Nierengarten of Wedbush Securities brings a handful of companies with technologies that could revolutionize medicine to investors' attention. (8/26/15) More >

Newsletter Briefs

"We believe ARNI is very good story for prostate and breast cancer indications." (9/2/15) Arno Therapeutics Inc. - The Life Sciences Report Interview with Ran Nussbaum More >

"SNSS does have a path forward in Europe, where it has a shot at approval for Qinprezo." (8/26/15) Sunesis Pharmaceuticals Inc. - The Life Sciences Report Interview with David Nierengarten More >

"HLTH recently acquired a marketing company to help fill its hospitals. Management has done a good job." (8/19/15) Nobilis Health Corp. - The Life Sciences Report Interview with Bruce Campbell More >

"When I can get potential blue-sky regenerative technologies like RP's at this small valuation, I'm buying." (8/12/15) RepliCel Life Sciences Inc. - The Life Sciences Report Interview with Eden Rahim More >

"BCLI is an inexpensive way to get exposure to a potential blockbuster technology." (8/12/15) BrainStorm Cell Therapeutics Inc. - The Life Sciences Report Interview with Eden Rahim More >

"CPHR is a decent risk/reward proposition." (8/12/15) Cipher Pharmaceuticals Inc. - The Life Sciences Report Interview with Eden Rahim More >

"RGS is actively seeking Japanese partners for its adipose-derived mesenchymal stem cell osteoarthritis drug, Progenza." (8/5/15) Regeneus Ltd. - The Life Sciences Report Interview with Colin Lee Novick More >

"AEMD has approved products that remove viruses, and is now also targeting breast cancer." (7/29/15) Aethlon Medical Inc. - The Life Sciences Report Interview with Caroline Corner More >

Expert Analysis

"RXII now may proceed with IRB submission for its Phase 1/2 AMD study." (9/1/15) RXi Pharmaceuticals Corp. - Mark Breidenbach, H.C. Wainwright & Co. More >

"The first patient was transplanted in STEM's Phase 2 dry AMD trial." (9/1/15) StemCells Inc. - Katherine Genis, Edison Investment Research More >

"We reiterate our Buy recommendation on HLTH." (8/31/15) Nobilis Health Corp. - Russell Stanley, Mackie Research Capital More >

"CANF is finalizing protocols for the next trials of CF101 in RA." (8/31/15) Can-Fite BioPharma Ltd. - Mark Breidenbach, H.C. Wainwright & Co. More >

"CPXX's fundamentals remain strong and we are optimistic about its prospects." (8/24/15) Celator Pharmaceuticals Inc. - Grant Zeng, Zacks Small-Cap Research More >

"We expect RNN's oncology pipeline, led by Archexin, to come into focus by year-end." (8/21/15) Rexahn Pharmaceuticals Inc. - Andrew Fein, H.C. Wainwright & Co. More >

"MSB's pipeline continues to mature steadily." (8/19/15) Mesoblast Ltd. - Katherine Genis, Edison Investment Research More >

"CYNA now boasts a solid balance sheet with a cash balance of roughly $110M." (8/20/15) Cynapsus Therapeutics Inc. - Anita Dushyanth, Zacks Small-Cap Research More >